• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Clear Street Launches Healthcare & Biotechnology Equity Research

    12/17/24 2:00:00 PM ET
    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $CGEM alert in real time by email

    Comprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises

    Clear Street, ("Clear Street", "the Company") a cloud-native financial technology firm on a mission to modernize the brokerage ecosystem, today announced the expansion of its recently launched equity research offering with the addition of Healthcare, initially focused on the biotechnology sector. The expanded research offering complements Clear Street's leading prime brokerage and clearing solutions for its rapidly growing client base of asset managers, institutions and professional traders across equities, fixed income, derivatives products and markets.

    Ed Tilly, President and CEO-Elect of Clear Street said, "The launch of our Healthcare Equity Research franchise demonstrates our commitment to providing capabilities that align with our clients' evolving needs. Our expanded equity research service complements our full suite of existing products and allows us to continue providing institutional clients the tools, teams and capabilities they need to navigate global markets and execute successful investment strategies."

    Led by Director of Research Mara Goldstein, the new Healthcare Research franchise provides in-depth market analysis and investment insights to the firm's expanding institutional client base. To launch coverage, Clear Street has appointed Kaveri Pohlman, Ph.D. and William "Bill" Maughan, Ph.D. as Managing Directors and Senior Equity Analysts, reporting to Ms. Goldstein.

    "Fueled by scientific advancements across all fields of medicine, the healthcare sector, particularly biotechnology, has grown immensely and has become a fundamentally important sector of the economy for investors," said Ms. Goldstein. "As the number of biotechnology companies continues to grow, we think it's important to be a voice in the space, analyzing and highlighting under-followed and under-represented companies that our clients, such as specialist hedge funds and dedicated healthcare fund investors care about."

    Dr. Kaveri Pohlman's research coverage will initially focus on oncology and autoimmune disease (I&I), spanning multiple technologies, from cell to gene therapy. Prior to joining Clear Street, Dr. Pohlman was a Senior Analyst at BTIG where she covered large and small-cap biotechnology companies. Dr. Pohlman earned a Ph.D. in molecular and cellular biology from SUNY Downstate Medical Center, an MS in biotechnology from New York University's Tandon School of Engineering and an MBA from Birla Institute of Management Technology.

    Dr. Bill Maughan brings deep experience in Equity Research across several therapeutic areas, and will continue to do so at Clear Street, including oncology, ophthalmology and genetic medicine, including RNA technologies. Prior to joining Clear Street, Dr. Maughan was a Senior Biotechnology Analyst with Canaccord Genuity, focusing on solid tumor oncology. Dr. Maughan earned a Ph.D. in Biochemistry, Cell and Molecular Biology at the Weill Cornell Graduate School of Medical Sciences and a bachelor's degree in Biological Sciences from Fordham University.

    Specific coverage launch includes:

    Healthcare: Biotechnology

    • Cargo Therapeutics (NASDAQ:CRGX)
    • Century Therapeutics (NASDAQ:IPSC)
    • Cullinan Therapeutics (NASDAQ:CGEM)
    • Delcath Systems (NASDAQ:DCTH)
    • Enliven Therapeutics (NASDAQ:ELVN)
    • Erasca (NASDAQ:ERAS)
    • Immatics (NASDAQ:IMTX)
    • Janux Therapeutics (NASDAQ:JANX)
    • MoonLake Immunotherapeutics (NASDAQ:MLTX)
    • Nuvation Bio (NYSE:NUVB)
    • Protagonist Therapeutics (NASDAQ:PTGX)
    • YmAbs Therapeutics (NASDAQ:YMAB)

    The launch of Healthcare Equity Research enhances Clear Street's growing research franchise and complements the Company's already existing product offerings across prime brokerage, professional clearing, futures trading and investment banking services. The expanding Equity Research offering demonstrates Clear Street's commitment to areas where institutional clients are actively seeking specialized insights. The Company also recently launched Clear Street UK, a pivotal step in building a global, full-service institutional business powered by cloud-based, financial technology.

    About Clear Street:

    Clear Street is modernizing the brokerage ecosystem with financial technology and services that empower market participants with real-time data and best-in-class products, tools and teams, to navigate capital markets around the world. Complemented by white-glove service, Clear Street's cloud-native, proprietary product suite delivers financing, derivatives, execution and more to power client success, adding efficiency to the market and enabling clients to minimize risk, redundancy and cost. Clear Street's goal is to create a single platform for every asset class, in every country and in any currency. For more information, visit https://clearstreet.io.

    Clear Street does not provide investment, legal, regulatory, tax, or compliance advice. Consult professionals in these fields to address your specific circumstances. These materials are: (i) solely an overview of Clear Street's products and services; (ii) provided for informational purposes only; and (iii) subject to change without notice or obligation to replace any information contained therein.

    Products and services are offered by Clear Street LLC as a Broker Dealer member FINRA and SIPC and a Futures Commission Merchant registered with the CFTC and member of NFA. Additional information about Clear Street is available on FINRA BrokerCheck, including its Customer Relationship Summary and NFA BASIC | NFA (futures.org).

    Copyright © 2024 Clear Street LLC. All rights reserved. Clear Street and the Shield Logo are Registered Trademarks of Clear Street LLC

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241217931998/en/

    Get the next $CGEM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CGEM
    $CRGX
    $DCTH
    $ELVN

    CompanyDatePrice TargetRatingAnalyst
    Janux Therapeutics Inc.
    $JANX
    7/11/2025$65.00Outperform
    Raymond James
    Protagonist Therapeutics Inc.
    $PTGX
    6/17/2025$72.00Buy
    Citigroup
    Enliven Therapeutics Inc.
    $ELVN
    6/16/2025$37.00Buy
    Goldman
    Cullinan Therapeutics Inc.
    $CGEM
    6/11/2025$22.00Buy
    Stifel
    Immatics N.V.
    $IMTX
    5/28/2025$10.00Buy
    Deutsche Bank
    MoonLake Immunotherapeutics
    $MLTX
    5/19/2025$61.00Peer Perform → Outperform
    Wolfe Research
    Nuvation Bio Inc.
    $NUVB
    4/23/2025$6.00Mkt Outperform
    Citizens JMP
    Y-mAbs Therapeutics Inc.
    $YMAB
    4/22/2025$3.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to three individuals whose employment commenced in June 2025. The grants resulted in the right to purchase 52,500 shares of the Company's common stock and are subject to the terms and conditions of the Company's 2023 Inducement Plan ("Plan"). The options were granted on June 30, 2025, the date the Compensation Committee approved the stock option included within the equity inducements a

      7/25/25 4:01:00 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

      PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses. TROP2-TRACTr adds first-in-class and best-in-class opportunity targeting multiple solid tumors with preclinical data supporting differentiated safety and efficacy potential. CD19-ARM displayed rapid, deep and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset while maintaining a large safety window in non-human primates, advancing toward first-in-human trials anticipated to begin in the first half of 2026. Webcast to be held today at 1:30 PM PT. Janux Therape

      7/24/25 4:05:00 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

      Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 8:00 a.m. ET to discuss its financial results and business updates for the second quarter of 2025. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-470-1428 (U.S. toll-free) and enter access code 926066. An archived recording will be available on Nuvation Bio's website for 90 days following the event.

      7/24/25 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

      Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-7) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 10/01/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

      10/2/24 4:43:10 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

      Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-3) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 05/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: Labeling

      5/23/24 10:32:08 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • FDA Approval for DANYELZA issued to Y-MABS THERAPEUTICS INC

      Submission status for Y-MABS THERAPEUTICS INC's drug DANYELZA (SUPPL-8) with active ingredient NAXITAMAB-GQGK has changed to 'Approval' on 03/20/2024. Application Category: BLA, Application Number: 761171, Application Classification:

      3/21/24 10:20:07 AM ET
      $YMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    SEC Filings

    See more
    • SEC Form SC 14D9 filed by CARGO Therapeutics Inc.

      SC 14D9 - CARGO Therapeutics, Inc. (0001966494) (Subject)

      7/23/25 4:52:41 PM ET
      $CRGX
    • SEC Form 144 filed by Protagonist Therapeutics Inc.

      144 - Protagonist Therapeutics, Inc (0001377121) (Subject)

      7/22/25 4:04:36 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC TO-T filed by CARGO Therapeutics Inc.

      SC TO-T - CARGO Therapeutics, Inc. (0001966494) (Subject)

      7/21/25 4:55:45 PM ET
      $CRGX

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Patel Dinesh V Ph D was granted 25,000 shares and sold $2,880,044 worth of shares (52,444 units at $54.92), decreasing direct ownership by 5% to 531,018 units (SEC Form 4)

      4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)

      7/23/25 6:57:03 PM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $278,646 worth of shares (12,500 units at $22.29) (SEC Form 4)

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      7/23/25 6:52:21 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND CEO Kintz Samuel sold $281,518 worth of shares (12,500 units at $22.52) (SEC Form 4)

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      7/21/25 7:21:09 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James initiated coverage on Janux Therapeutics with a new price target

      Raymond James initiated coverage of Janux Therapeutics with a rating of Outperform and set a new price target of $65.00

      7/11/25 8:13:15 AM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on Protagonist Therapeutics with a new price target

      Citigroup initiated coverage of Protagonist Therapeutics with a rating of Buy and set a new price target of $72.00

      6/17/25 7:50:36 AM ET
      $PTGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Enliven Therapeutics with a new price target

      Goldman initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $37.00

      6/16/25 7:46:51 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Sjogren Colleen bought $90,350 worth of shares (50,000 units at $1.81), increasing direct ownership by 161% to 81,000 units (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      6/18/25 4:05:15 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF PEOPLE OFFICER Markel Stacy bought $17,100 worth of shares (10,000 units at $1.71), increasing direct ownership by 51% to 29,591 units (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      6/18/25 4:05:21 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Sauvage Philippe bought $13,216 worth of shares (7,300 units at $1.81), increasing direct ownership by 281% to 9,902 units (SEC Form 4)

      4 - Nuvation Bio Inc. (0001811063) (Issuer)

      6/18/25 4:05:19 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Financials

    Live finance-specific insights

    See more
    • Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

      Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 8:00 a.m. ET to discuss its financial results and business updates for the second quarter of 2025. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-470-1428 (U.S. toll-free) and enter access code 926066. An archived recording will be available on Nuvation Bio's website for 90 days following the event.

      7/24/25 4:05:00 PM ET
      $NUVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Delcath Systems to Host Second Quarter 2025 Earnings Call

      Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 6, 2025, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Wednesday, August 6, 2025 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1723203&tp_key=fbe0333159 A replay of the webinar will be availab

      7/23/25 4:01:00 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

      Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels with 90 patients enrolled and a median treatment duration of ~29 weeks at cutoff Enliven will host a webcast and conference call today, June 13, at 1:30 p.m. ET BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutic

      6/13/25 6:02:00 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Century Therapeutics Inc.

      SC 13G - Century Therapeutics, Inc. (0001850119) (Subject)

      11/27/24 6:51:58 PM ET
      $IPSC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

      SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

      11/15/24 10:33:51 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

      SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

      11/14/24 9:46:56 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

      PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses. TROP2-TRACTr adds first-in-class and best-in-class opportunity targeting multiple solid tumors with preclinical data supporting differentiated safety and efficacy potential. CD19-ARM displayed rapid, deep and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset while maintaining a large safety window in non-human primates, advancing toward first-in-human trials anticipated to begin in the first half of 2026. Webcast to be held today at 1:30 PM PT. Janux Therape

      7/24/25 4:05:00 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

      Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that it will host a virtual R&D Day at 1:30 PM PT on Thursday, July 24, 2025. The event will include a presentation from management highlighting product candidates identified from its preclinical pipeline to move into clinical trials. These previously undisclosed preclinical programs utilize Janux's expertise and platform technologies to potentially address significant unmet medical needs.

      7/17/25 4:30:00 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

      6/30/25 11:02:00 AM ET
      $ARAY
      $CLRB
      $ERAS
      $INTS
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)